Biophytis SA Book Value 2011-2026 | BPTS

Book value is a financial metric that reflects the value of a company's assets minus its liabilities as of a specific date, according to accounting records. In simple terms, it is the amount that would remain for the owners of the company if all assets were sold and all debts paid off.

What is included in book value

Assets — all company resources: real estate, equipment, inventory, cash, accounts receivable, and others.
Liabilities — all debts and financial obligations: loans, accounts payable, taxes, and other obligations.

Features of the metric

Assessment of the company's "real" value
Book value shows how much the company is worth according to accounting data, that is, the value of its property taking debts into account.
Comparison with market capitalization
Comparing book value and the market price of shares helps to understand whether the company is overvalued or undervalued by the market.
Indicator of financial stability
If the book value is high, it indicates the company has significant assets, which reduces risks for investors.
Key component for financial ratios
Many metrics, such as the price-to-book ratio (P/B), use book value to analyze the attractiveness of shares.

Annual Book Value Biophytis SA

2023	2022	2021	2020	2019	2018	2017	2016	2015	2014	2013	2012	2011
-	-	34.9 M	6.83 M	-7.53 M	7.01 M	21.2 M	4.52 M	11.7 M	-1.13 M	-409 K	126 K	-

All numbers in EUR currency

Indicator range from annual reports

Maximum	Minimum	Average
34.9 M	-7.53 M	7.71 M

Quarterly Book Value Biophytis SA

2022-Q4	2022-Q3	2022-Q2	2022-Q1	2021-Q4	2021-Q3	2021-Q2	2021-Q1	2020-Q4	2020-Q3	2020-Q2	2020-Q1	2019-Q4	2019-Q3	2019-Q2	2019-Q1	2018-Q4	2018-Q3	2018-Q2	2018-Q1	2017-Q4	2017-Q3	2017-Q2	2017-Q1	2016-Q4	2016-Q3	2016-Q2	2016-Q1	2015-Q4	2015-Q3	2015-Q2	2015-Q1	2014-Q4	2014-Q3	2014-Q2	2014-Q1	2013-Q4	2013-Q3	2013-Q2	2013-Q1	2012-Q4	2012-Q3	2012-Q2	2012-Q1	2011-Q4	2011-Q3	2011-Q2	2011-Q1
-	-	-	-	36.3 M	-	-	-	27.2 M	-	-	-	17.7 M	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-

All numbers in EUR currency

Indicator range from quarterly reporting

Maximum	Minimum	Average
36.3 M	17.7 M	27 M

Book Value of other stocks in the Biotechnology industry

Issuer	Book Value	Price	% 24h	Market Cap	Country
MorphoSys AG MOR	49 M	-	2.43 %	$ 254 M	Germany
Aptorum Group Limited APM	11.8 M	$ 0.79	-1.15 %	$ 4.31 M	China
Acorda Therapeutics ACOR	109 M	-	-24.86 %	$ 820 K	USA
AbCellera Biologics ABCL	967 M	$ 3.49	0.58 %	$ 1.04 B	Canada
Frequency Therapeutics FREQ	51.4 M	-	-	$ 528 M	USA
argenx SE ARGX	5.5 B	$ 700.45	-1.19 %	$ 25 B	Niderland
I-Mab IMAB	5.63 B	-	-	$ 866 M	China
AgeX Therapeutics AGE	5.36 M	-	-10.17 %	$ 12.2 K	USA
Alexion Pharmaceuticals, Inc. ALXN	253 M	-	-	$ 40.3 B	USA
Alterity Therapeutics Limited ATHE	35.5 M	$ 3.6	1.41 %	$ 8.66 B	Australia
Grifols, S.A. GRFS	8.61 B	$ 7.81	-2.01 %	$ 6.83 B	Spain
Aeglea BioTherapeutics AGLE	715 M	-	-	$ 1.01 B	USA
Ascendis Pharma A/S ASND	-163 M	$ 225.98	-1.32 %	$ 5 B	Danmark
Applied Genetic Technologies Corporation AGTC	29.5 M	-	-	$ 26.5 M	USA
EyeGate Pharmaceuticals, Inc. EYEG	2.33 B	-	-1.52 %	$ 24.7 M	USA
ADC Therapeutics SA ADCT	88.7 M	$ 4.13	-5.06 %	$ 105 M	Schweiz
Akero Therapeutics AKRO	750 M	-	-	$ 3.67 B	USA
Adverum Biotechnologies ADVM	70.7 M	-	-	$ 86.2 M	USA
Midatech Pharma plc MTP	8.32 M	-	-18.52 %	$ 27.3 M	Britain
Akouos AKUS	234 M	-	0.23 %	$ 488 M	USA
Advaxis ADXS	16.6 M	-	-9.65 %	$ 45.9 M	USA
Allena Pharmaceuticals ALNA	18.9 M	-	3.16 %	$ 1.9 M	USA
Aileron Therapeutics ALRN	54.4 M	-	10.36 %	$ 9.8 M	USA
BioCardia BCDA	-1.6 M	$ 1.26	-0.79 %	$ 26.7 M	USA
AlloVir ALVR	113 M	-	4.14 %	$ 49.1 M	USA
Applied Molecular Transport AMTI	60.8 M	-	-	$ 10.1 M	USA
Институт стволовых клеток человека ISKJ	10.6 M	-	-	-	Russia
Anika Therapeutics ANIK	271 M	$ 14.2	-0.7 %	$ 208 M	USA
Aptose Biosciences APTO	-4.54 M	-	-45.71 %	$ 1.2 M	Canada
Acer Therapeutics ACER	-16.8 M	-	2.71 %	$ 14 M	USA
ARCA biopharma ABIO	382 M	-	1052.0 %	$ 415 M	USA
Aeterna Zentaris AEZS	13.2 M	-	5.93 %	$ 314 M	Canada
Athersys ATHX	60.2 M	-	3.77 %	$ 22.4 M	USA
BioNTech SE BNTX	19.2 B	$ 91.19	1.21 %	$ 27.2 B	Germany
Aptinyx APTX	38.3 M	-	-39.0 %	$ 4.57 M	USA
Avenue Therapeutics ATXI	1.86 M	-	-52.27 %	$ 4.45 M	USA
Autolus Therapeutics plc AUTL	427 M	$ 1.44	-1.37 %	$ 367 M	Britain
Arcturus Therapeutics Holdings ARCT	214 M	$ 6.68	-4.57 %	$ 183 M	Israel
Acasti Pharma ACST	66.6 M	-	4.01 %	$ 150 M	Canada
AVEO Pharmaceuticals AVEO	45.9 M	-	-	$ 521 M	USA
Burford Capital Limited BUR	1.66 B	$ 7.92	1.67 %	$ 1.31 B	Britain
Ayala Pharmaceuticals AYLA	7.77 M	-	-	$ 7.46 M	Israel
Aytu BioScience AYTU	124 M	$ 2.54	-5.22 %	$ 16 M	USA
Certara CERT	1.06 B	$ 6.67	1.6 %	$ 1.07 B	USA
Athira Pharma ATHA	44.8 M	-	-	$ 269 M	USA
Can-Fite BioPharma Ltd. CANF	20.3 M	$ 3.6	-4.0 %	$ 7.83 B	Israel
CureVac N.V. CVAC	688 M	-	-	$ 867 M	Germany
Aravive ARAV	10.7 M	-	-13.39 %	$ 1.45 M	USA
Brainstorm Cell Therapeutics BCLI	-7.76 M	-	-2.5 %	$ 5.88 M	USA